TLC BIOPHARMACEUTICALS INC has a total of 34 patent applications. It increased the IP activity by 600.0%. Its first patent ever was published in 2010. It filed its patents most often in Australia, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, environmental technology and machines are INDIA GLOBALIZATION CAPITAL INC, CONFLUENCE PHARMACEUTICALS LLC and ICDPHARMA LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 10 | |
#2 | WIPO (World Intellectual Property Organization) | 6 | |
#3 | Canada | 4 | |
#4 | China | 3 | |
#5 | EPO (European Patent Office) | 3 | |
#6 | Republic of Korea | 3 | |
#7 | Taiwan | 2 | |
#8 | United States | 2 | |
#9 | Israel | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Environmental technology | |
#3 | Machines | |
#4 | Biotechnology | |
#5 | Medical technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Climate change adaptation technologies | |
#4 | Unspecified technologies | |
#5 | Peptides | |
#6 | Electrotherapy |
# | Name | Total Patents |
---|---|---|
#1 | Hong Keelung | 26 |
#2 | Tseng Yun-Long | 16 |
#3 | Kao Hao-Wen | 12 |
#4 | Lin Yi-Yu | 12 |
#5 | Yu Wan-Ni | 11 |
#6 | Guo Luke S S | 9 |
#7 | Shih Sheue-Fang | 8 |
#8 | Chang Po-Chun | 6 |
#9 | Fang Jonathan | 6 |
#10 | Cheng Ting-Yu | 5 |
Publication | Filing date | Title |
---|---|---|
WO2020220000A1 | Liposomal sustained-release compositions containing a therapeutic drug and use thereof | |
AU2019339528A1 | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain | |
AU2019245447A1 | Sustained-release anesthetic compositions and methods of preparation thereof | |
KR20200044902A | Sustained-release anesthetic composition and method for manufacturing same | |
US2014193486A1 | Sustained releasing composition via local injection for treating eye diseases | |
AU2013216861A1 | Pharmaceutical compositions to reduce complications of ocular steroid |